Coxsackie-infection: antibodies to Coxsackie viruses in the blood
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Coxsackie viruses are represented by two groups: the Coxsackie A group, which includes 23 serovariants (A1-A22, 4), and the Coxsackie group B, including six serovariants (B1-B6). Coxsackie A and B viruses cause poliomyelitis-like diseases in humans, in 20-40% of patients under the age of 20, the infection is complicated by myocarditis. There is some connection between the serovariant of the virus and the nature of the clinical manifestations of the infection. Thus, the Coxsacki virus A16 causes damage to the mucous membrane of the mouth, paresis of the limbs, Coxsacki A24 - acute hemorrhagic conjunctivitis, Coxsaki from B1 to B5 - pericarditis, myocarditis and fulminant encephalomyocarditis. For the diagnosis of Coxsackie infection, serological methods are used - RSK, RTGA and neutralization reaction.
With the use of RSK, RTGA and neutralization reaction, antibodies to Coxsackie viruses in serum are detected . Investigate paired sera in the acute period of infection and 2-3 weeks after the onset of the disease. In favor of infection, an increase in antibody titer of at least 4-fold is indicated. It should be noted that such titer changes can not be detected very rarely, therefore the evaluation of research results causes great difficulties. RSK allows to identify specific antibodies separately to each serovariant of Coxsackie virus B (from B1 to B6).
[